LXRX Stock Price, Lexicon Pharmaceuticals Quote, Chart

Market Summary

USD1.770.00

Market Closed

0.00%

LXRX Stock Price

View Fullscreen

LXRX RSI Chart

LXRX Valuation

Market Cap

435.8M

Price/Earnings (Trailing)

-2.25

Price/Sales (Trailing)

361.84

EV/EBITDA

-5.58

Price/Free Cashflow

-2.35

LXRX Price/Sales (Trailing)

LXRX Profitability

EBT Margin

-7285.84%

Return on Equity

-67.01%

Return on Assets

-46.4%

Free Cashflow Yield

-42.59%

LXRX Fundamentals

LXRX Revenue

Revenue (TTM)

1.2M

Rev. Growth (Yr)

2.4K%

Rev. Growth (Qtr)

333.02%

LXRX Earnings

Earnings (TTM)

-193.6M

Earnings Growth (Yr)

-51.55%

Earnings Growth (Qtr)

2.73%

Breaking Down LXRX Revenue

52 Week Range

1.82

(Low)(High)

Last 7 days

15.6%

Last 30 days

-13.6%

Last 90 days

-17.2%

Trailing 12 Months

-45.4%

How does LXRX drawdown profile look like?

LXRX Financial Health

Current Ratio

15.58

Debt/Equity

0.35

Debt/Cashflow

-1.86

LXRX Investor Care

Shares Dilution (1Y)

30.27%

Diluted EPS (TTM)

-0.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	126.0K	408.0K	531.0K	1.2M
2022	0	306.0K	111.0K	116.0K
2021	18.1M	12.1M	6.2M	298.0K
2020	320.9M	320.3M	32.5M	24.0M
2019	47.1M	42.9M	330.4M	322.1M
2018	99.1M	100.8M	80.1M	63.2M
2017	88.8M	80.8M	80.8M	91.7M
2016	140.7M	160.4M	187.6M	83.3M
2015	24.4M	24.1M	24.2M	130.0M
2014	2.1M	2.6M	2.8M	22.9M
2013	1.1M	1.2M	1.0M	2.2M
2012	1.6M	1.2M	1.2M	1.1M
2011	3.9M	3.2M	2.8M	1.8M
2010	0	8.8M	6.8M	4.9M
2009	0	0	0	10.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lexicon Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 28, 2024	lefkowitz robert j md	acquired	-	-	8,032	-
Apr 28, 2024	debbane raymond	acquired	-	-	8,032	-
Apr 28, 2024	swain judith l	acquired	-	-	8,032	-
Apr 28, 2024	amouyal philippe	acquired	-	-	8,032	-
Apr 28, 2024	sobecki christopher j	acquired	-	-	8,032	-
Apr 28, 2024	barker sam l	acquired	-	-	8,032	-
Mar 13, 2024	artal international s.c.a.	acquired	124,875,000	108	1,150,920	-
Feb 28, 2024	wade jeffrey l	acquired	-	-	97,564	president and cfo
Feb 28, 2024	alexander kristen	sold (taxes)	-30,897	2.62	-11,793	vp, finance and accounting
Feb 28, 2024	granowitz craig b	sold (taxes)	-81,914	2.62	-31,265	svp, chief medical officer

Which funds bought or sold LXRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-370	-	-%
May 06, 2024	SG Americas Securities, LLC	reduced	-56.00	-21,000	46,000	-%
May 06, 2024	Nordwand Advisors, LLC	new	-	9,600	9,600	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	reduced	-62.4	-490,000	704,000	0.06%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	reduced	-2.54	26,040	75,286	-%
May 03, 2024	SIGNATUREFD, LLC	reduced	-27.13	353	2,818	-%
May 03, 2024	Avion Wealth	unchanged	-	-	1,000	-%
May 02, 2024	Daiwa Securities Group Inc.	unchanged	-	-	1,000	-%
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	new	-	118	118	-%
May 01, 2024	Pinnacle Wealth Management Advisory Group, LLC	unchanged	-	10,827	29,868	-%

Are Funds Buying or Selling LXRX?

Are funds buying LXRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LXRX

No. of Funds

Unveiling Lexicon Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 13, 2024	invus, l.p.	15.8%	38,918,903	SC 13D/A
Feb 14, 2024	biotechnology value fund l p	5.1%	12,599,302	SC 13G/A
Jun 06, 2023	invus, l.p.	15.9%	38,918,903	SC 13D/A
Feb 14, 2023	biotechnology value fund l p	4.6%	8,686,034	SC 13G/A
Aug 01, 2022	invus, l.p.	21.2%	38,918,903	SC 13D/A
Feb 14, 2022	biotechnology value fund l p	5.1%	7,557,501	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Jan 21, 2021	invus, l.p.	27.5%	38,918,903	SC 13D/A
Jan 11, 2021	fmr llc	-	0	SC 13G/A
Jan 05, 2021	invus, l.p.	27.5%	38,918,903	SC 13D/A

Recent SEC filings of Lexicon Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Mar 26, 2024	ARS	ARS

Peers (Alternatives to Lexicon Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Lexicon Pharmaceuticals Inc News

Latest updates

Lexicon Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	701,500	162,000	317,000	24,000	28,000	39,000	35,000	14,000	23,000	234,000	216,500	199,000	6,634,000	9,163,000	7,999,000	8,727,000	294,448,000	9,682,000	9,216,000	17,071,000
Costs and Expenses	-2.1%	46,463,000	47,438,500	49,793,000	44,557,000	31,166,000	30,306,000	23,134,000	24,042,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-31,166,000	77,482,000	-23,134,000	-24,042,000	25,344,000	22,985,000	18,193,000	20,866,000	7,424,000	52,777,000	73,742,000	70,437,000	55,944,000	69,772,000	28,227,000	26,685,000	29,439,000
S&GA Expenses	-1.7%	32,060,000	32,607,000	32,228,000	-	19,140,000	16,329,000	12,577,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-2.6%	14,372,000	14,762,000	17,558,000	14,541,000	12,026,000	13,977,000	10,557,000	13,356,000	16,498,000	15,682,000	10,257,000	12,609,000	992,000	40,147,000	57,301,000	55,181,000	40,606,000	26,659,000	12,637,000	12,022,000	12,307,000
EBITDA Margin	1.9%	-62.84	-64.06	-148	-201	-661	-733	-768	-281	-290	39.74	20.74	14.26	10.98	-	-	-	-	-	-	-	-
Interest Expenses	37.6%	3,257,000	2,367,000	3,899,000	1,960,000	1,821,000	612,000	864,000	703,000	292,000	171,000	169,000	167,000	170,000	4,118,000	5,125,000	5,131,000	5,191,000	5,204,000	5,164,000	5,117,000	5,225,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,495,000	82,603,000	-	-	-51,138,000	220,072,000	-	-	-16,577,000
EBT Margin	0%	-72.86	-72.86	-165	-215	-696	-756	-790	-286	-294	39.54	20.26	13.62	10.25	-	-	-	-	-	-	-	-
Net Income	2.7%	-48,397,000	-49,756,000	-50,525,000	-44,904,000	-31,934,000	-30,494,000	-23,387,000	-24,587,000	-34,644,500	-23,122,000	-	-20,958,000	-38,800,500	82,603,000	-69,071,000	-	-51,138,000	226,086,000	-	-	-16,782,000
Net Income Margin	-9.3%	-160	-147	-297	-320	-876	-878	-955	-345	-264	-13.32	1.88	-2.56	-1.05	-	-	-	-	-	-	-	-
Free Cashflow	-9.1%	-55,130,000	-50,548,000	-41,702,000	-38,256,000	-31,861,000	-22,815,000	-19,443,000	-24,422,000	-22,851,000	-17,363,000	-22,827,000	-25,197,000	-34,293,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	81.9%	417	229	276	317	163	194	192	112	136	137	172	172	193	204	179	323	371	418	445	233	259
Current Assets	106.5%	365	177	223	264	110	141	139	65.00	88.00	89.00	124	123	145	158	122	246	292	338	364	122	147
Cash Equivalents	329.5%	96.00	22.00	21.00	102	26.00	46.00	19.00	21.00	60.00	64.00	92.00	90.00	98.00	126	52.00	87.00	56.00	36.00	170	11.00	46.00
Inventory	34.9%	1.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	4.00	4.00	4.00	4.00	4.00	5.00
Net PPE	-7.2%	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	11.00	12.00	14.00	14.00	15.00	15.00	15.00
Goodwill	0%	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00
Liabilities	-5.8%	128	136	137	130	75.00	77.00	48.00	41.00	43.00	23.00	36.00	34.00	41.00	47.00	91.00	333	316	301	280	298	304
Current Liabilities	-25.8%	23.00	32.00	32.00	26.00	20.00	23.00	18.00	17.00	19.00	22.00	34.00	33.00	39.00	47.00	79.00	98.00	80.00	65.00	45.00	22.00	28.00
Long Term Debt	0.4%	100	100	99.00	99.00	49.00	49.00	24.00	24.00	23.00	-	-	-	-	-	12.00	235	234	234	234	244	244
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	12.00	12.00	12.00	12.00	9.00	10.00	11.00	11.00	11.00	1.00	1.00
LT Debt, Non Current	-100.0%	-	100	99.00	99.00	49.00	49.00	24.00	24.00	23.00	-	-	-	-	-	12.00	235	234	234	234	244	244
Shareholder's Equity	210.2%	289	93.00	140	186	88.00	117	144	71.00	93.00	114	137	137	153	156	88.00	-	55.00	117	165	-	-
Retained Earnings	-2.7%	-1,815	-1,766	-1,717	-1,666	-1,621	-1,589	-1,559	-1,535	-1,511	-1,487	-1,462	-1,439	-1,420	-1,400	-1,394	-1,477	-1,408	-1,341	-1,290	-1,516	-1,493
Additional Paid-In Capital	13.2%	2,108	1,863	1,859	1,856	1,713	1,709	1,706	1,609	1,606	1,609	1,606	1,584	1,581	1,561	1,487	1,471	1,467	1,462	1,459	1,455	1,451
Accumulated Depreciation	3.2%	5.00	5.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	64.00	63.00	61.00	62.00	62.00	62.00	62.00
Shares Outstanding	11.4%	246	221	213	197	189	166	175	149	149	146	146	144	143	-	-	-	-	-	-	-	-
Float	-	-	-	-	274	-	-	-	134	-	-	-	309	-	-	-	82.00	-	-	-	260	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-9.1%	-55,130	-50,548	-41,619	-38,117	-31,613	-21,569	-19,439	-24,422	-23,421	-22,828	-17,150	-21,880	-25,159	-34,239	-40,378	-46,298	-22,054	-24,371	190,698	-26,900	-25,620
Share Based Compensation	33.9%	4,302	3,212	3,898	3,815	3,415	3,268	2,648	2,832	2,772	2,228	2,712	2,786	2,851	2,680	1,904	4,258	4,432	3,479	3,562	3,766	3,411
Cashflow From Investing	-312.4%	-110,224	51,898	-39,326	-74,608	12,093	24,174	-77,196	-13,648	-4,408	6,096	-400	14,138	-17,724	44,101	215,803	78,074	42,778	-109,398	-31,281	-7,450	-7,726
Cashflow From Financing	23938400.0%	239,383	-1.00	-210	188,995	-824	24,906	94,019	-	23,284	-11,321	19,781	-23.00	14,272	64,150	-210,117	-425	-1,244	-322	-320	-322	-1,262
Buy Backs	-	1,730	-	-	-	824	-	-	-	864	-	-	-	2,675	-	-	103	923	-	-	-	941

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LXRX Income Statement

2024-03-31

Condensed Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Net product revenue	$ 1,093	$ 0
Royalties and other revenue	37	24
Total revenues	1,130	24
Operating expenses:
Cost of sales	31	0
Research and development, including stock-based compensation of $1,594 and $1,203, respectively	14,372	12,026
Selling, general and administrative, including stock-based compensation of $2,708 and $2,212, respectively	32,060	19,140
Total operating expenses	46,463	31,166
Loss from operations	(45,333)	(31,142)
Interest and other expense	(4,948)	(1,821)
Interest income and other, net	1,884	1,029
Net loss	$ (48,397)	$ (31,934)
Net loss per common share, basic (usd per share)	$ (0.20)	$ (0.17)
Net loss per common share, diluted (usd per share)	$ (0.20)	$ (0.17)
Shares used in computing net loss per common share, basic	245,390	189,014
Shares used in computing net loss per common share, diluted	245,390	189,014
Other comprehensive loss:
Unrealized (loss) gain on investments	$ (81)	$ 265
Comprehensive loss	$ (48,478)	$ (31,669)

LXRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 96,494	$ 22,465
Short-term investments	259,104	147,561
Accounts receivable, net	1,526	1,010
Inventory	514	381
Prepaid expenses and other current assets	7,009	5,130
Total current assets	364,647	176,547
Property and equipment, net of accumulated depreciation and amortization of $4,682 and $4,538, respectively	1,843	1,987
Goodwill	44,543	44,543
Operating lease right-of-use-assets	5,358	5,524
Other assets	828	828
Total assets	417,219	229,429
Current liabilities:
Accounts payable	8,067	14,389
Accrued liabilities	15,332	17,157
Total current liabilities	23,399	31,546
Long-term debt, net	99,874	99,508
Long-term operating lease liabilities	5,079	5,265
Total liabilities	128,352	136,319
Commitments and contingencies (Note 6)
Stockholders’ Equity:
Series A Convertible preferred stock, 2,304,147 and no shares issued, respectively	23	0
Common stock, $0.001 par value; 300,000,000 shares authorized; 247,764,761 and 245,792,668 shares issued, respectively	248	245
Additional paid-in capital	2,108,497	1,862,558
Accumulated deficit	(1,815,236)	(1,766,839)
Accumulated other comprehensive income/(loss)	(50)	31
Treasury stock, at cost, 1,528,008 and 867,973 shares, respectively	(4,615)	(2,885)
Total stockholders’ equity	288,867	93,110
Total liabilities and stockholders’ equity	$ 417,219	$ 229,429

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

CEO	Mr. Lonnel Coats
WEBSITE	lexpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	135

Lexicon Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Lexicon Pharmaceuticals Inc? What does LXRX stand for in stocks?

LXRX is the stock ticker symbol of Lexicon Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lexicon Pharmaceuticals Inc (LXRX)?

As of Tue May 07 2024, market cap of Lexicon Pharmaceuticals Inc is 435.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LXRX stock?

You can check LXRX's fair value in chart for subscribers.

What is the fair value of LXRX stock?

You can check LXRX's fair value in chart for subscribers. The fair value of Lexicon Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lexicon Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LXRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lexicon Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether LXRX is over valued or under valued. Whether Lexicon Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Lexicon Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LXRX.

What is Lexicon Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, LXRX's PE ratio (Price to Earnings) is -2.25 and Price to Sales (PS) ratio is 361.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LXRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lexicon Pharmaceuticals Inc's stock?

In the past 10 years, Lexicon Pharmaceuticals Inc has provided -0.158 (multiply by 100 for percentage) rate of return.